Actinium Ac 225-DOTA-Daratumumab

{
  "id": "MLC-T-ONC-009624",
  "term": "Actinium Ac 225-DOTA-Daratumumab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-daratumumab, the monoclonal antibody moiety specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.",
  "synonyms": [
    "[225Ac]-DOTA-daratumumab",
    "225Ac-DOTA-daratumumab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/actinium-ac-225-dota-daratumumab/"
}